The June quarter results reveal a company grappling with sequential headwinds despite maintaining robust year-on-year comparisons. Revenue declined 3.00% quarter-on-quarter to ₹1,963.48 crores, marking the first sequential contraction in recent quarters after a strong growth trajectory through FY26. More concerning for investors is the compression in profitability metrics, with operating margins (excluding other income) contracting 162 basis points sequentially to 22.32%, whilst PAT margins declined 169 basis points to 11.04%.
The sequential profit decline of 15.88% to ₹216.81 crores represents a notable reversal from the previous quarter's performance, raising questions about the sustainability of the company's margin profile and operational efficiency. However, the year-on-year comparison remains encouraging, with net profit up 45.94% from ₹148.56 crores in Q1 FY26, reflecting the company's strong growth trajectory over the past year.
Quarterly Performance Trend: Growth Momentum Stalls
| Quarter | Revenue (₹ Cr) | QoQ % | Net Profit (₹ Cr) | QoQ % | Operating Margin | PAT Margin |
|---|---|---|---|---|---|---|
| Jun'26 | 1,963.48 | -3.00% | 216.81 | -15.88% | 22.32% | 11.04% |
| Mar'26 | 2,024.26 | +2.69% | 257.73 | -3.71% | 23.94% | 12.73% |
| Dec'25 | 1,971.15 | +18.85% | 267.66 | +6.71% | 25.93% | 13.58% |
| Sep'25 | 1,658.50 | +7.77% | 250.83 | +68.84% | 25.03% | 15.12% |
| Jun'25 | 1,538.94 | -1.88% | 148.56 | -18.63% | 22.49% | 9.65% |
| Mar'25 | 1,568.48 | +7.94% | 182.57 | -15.83% | 23.78% | 11.64% |
| Dec'24 | 1,453.07 | — | 216.91 | — | 26.99% | 14.93% |
The quarterly trend table reveals a concerning pattern of margin erosion. Operating margins have declined from a peak of 26.99% in December 2024 to 22.32% in the latest quarter, representing a compression of 467 basis points over two quarters. Similarly, PAT margins have contracted from 15.12% in September 2025 to 11.04% currently, indicating rising cost pressures and operational challenges.
Financial Performance: Profitability Under Pressure
Sagility's Q1 FY27 financial performance reveals multiple headwinds converging simultaneously. Net sales declined 3.00% sequentially to ₹1,963.48 crores, breaking a multi-quarter growth streak. This revenue softness, combined with margin compression, resulted in a sharper 15.88% decline in net profit to ₹216.81 crores. The operating profit (PBDIT excluding other income) fell to ₹438.16 crores from ₹484.66 crores in the previous quarter, reflecting both lower revenue and margin pressures.
Employee costs, the company's largest expense category, remained elevated at ₹1,227.59 crores in Q1 FY27, representing 62.52% of revenue compared to 63.08% in the previous quarter. Whilst this shows marginal improvement in employee cost ratio, the absolute decline in employee expenses was insufficient to offset the revenue contraction, leading to margin compression. The company's gross profit margin declined 291 basis points sequentially to 21.16%, indicating pricing pressures or unfavourable business mix shifts.
Other income declined significantly to ₹14.32 crores in Q1 FY27 from ₹24.78 crores in the previous quarter, removing a cushion that had supported overall profitability. The effective tax rate for the quarter stood at 24.58%, down from 29.04% in Q4 FY26, providing some relief to bottom-line performance. Interest costs remained stable at ₹21.89 crores, reflecting the company's manageable debt position.
⚠️ Margin Compression Alert
Operating margins have contracted 467 basis points from their December 2024 peak of 26.99% to the current 22.32%, whilst PAT margins have declined from 15.12% to 11.04% over the same period. This sustained margin erosion, combined with sequential revenue decline, raises concerns about pricing power, cost management, and business mix optimisation. Investors should closely monitor whether this represents temporary headwinds or structural challenges in the company's business model.
Operational Dynamics: Return Ratios Remain Subdued
Sagility's return on equity (ROE) stands at a modest 8.16% on average, significantly below the peer group average of approximately 23% and well below best-in-class IT services companies that typically generate ROE above 20%. The latest ROE of 9.84% represents an improvement from historical levels but remains in the lower quartile of the industry, indicating suboptimal capital efficiency and profitability relative to shareholder equity deployed.
The company's return on capital employed (ROCE) of 12.87% similarly lags industry leaders, though it reflects improvement from earlier periods. For a capital-light business process management company, these return metrics suggest either aggressive pricing to win market share, operational inefficiencies, or a business model that requires substantial investment relative to profitability generated. The company's debt-to-equity ratio of 0.12 times is admirably low, indicating conservative financial leverage and strong balance sheet health.
On the balance sheet front, Sagility maintains a solid financial position with shareholder funds of ₹8,336.05 crores as of March 2025, up from ₹6,443.13 crores in the previous year. Long-term debt declined substantially to ₹567.04 crores from ₹1,664.70 crores, demonstrating effective deleveraging. Fixed assets stood at ₹8,445.18 crores, reflecting the company's infrastructure investments, whilst current assets of ₹1,820.77 crores provide adequate liquidity. The company generated robust cash flow from operations of ₹1,214.00 crores in FY25, up from ₹973.00 crores in FY24, indicating healthy underlying cash generation despite profitability challenges.
Capital Efficiency Challenge
Sagility's ROE of 8.16% and ROCE of 12.87% position it in the bottom quartile of IT services companies, raising questions about capital deployment efficiency. For a business process management company with relatively low capital intensity, these returns suggest either aggressive pricing strategies, operational inefficiencies, or a business model requiring optimisation. The company's ability to improve these metrics will be critical for justifying its valuation and attracting long-term investors.
Industry Context: Navigating Healthcare BPM Headwinds
The healthcare business process management sector has experienced mixed demand dynamics, with some clients optimising costs whilst others invest in digital transformation. Sagility operates in a specialised niche focused on healthcare payers and providers, offering revenue cycle management, claims processing, and customer service solutions. The company faces competition from both large IT services firms expanding into healthcare BPM and specialised players with deep domain expertise.
The sequential revenue decline in Q1 FY27 may reflect seasonal patterns, client-specific project completions, or broader demand softness in the healthcare BPM space. The margin compression suggests either pricing pressures from competitive intensity or inefficiencies in service delivery that need addressing. The company's ability to maintain its year-on-year growth trajectory of 27.59% in revenue and 45.94% in profit demonstrates underlying business strength, but the sequential trends warrant close monitoring.
Peer Comparison: Valuation Discount Reflects Concerns
| Company | P/E (TTM) | P/BV | ROE % | Debt/Equity | Div Yield |
|---|---|---|---|---|---|
| Sagility | 20.61x | 2.03x | 8.16% | 0.12x | — |
| Inventurus Knowledge | 44.71x | 14.40x | 29.68% | 0.24x | — |
| Tata Technologies | 52.45x | 7.54x | 18.04% | -0.15x | 1.60% |
| Netweb Technologies | 117.79x | 41.89x | 22.25% | -0.43x | 0.06% |
| Affle 3i | 47.36x | 5.90x | 14.43% | -0.35x | — |
| Tata Elxsi | 29.72x | 7.09x | 30.52% | -0.55x | 2.17% |
Sagility trades at a significant valuation discount to its peer group, with a P/E ratio of 20.61x compared to the peer average of approximately 58x. This discount reflects investor concerns about the company's lower profitability metrics, with ROE of 8.16% substantially below the peer average of 23%. The company's price-to-book ratio of 2.03x is also the lowest in the peer set, indicating that the market assigns lower quality premium to Sagility's earnings and assets compared to peers.
The valuation discount appears justified given the fundamental performance gap. Whilst Sagility maintains conservative leverage at 0.12x debt-to-equity (better than most peers), its return ratios lag significantly. The company does not pay dividends, unlike Tata Technologies (1.60% yield) and Tata Elxsi (2.17% yield), removing an income component for investors. For the valuation gap to narrow, Sagility would need to demonstrate sustained margin improvement and ROE expansion towards peer levels.
Valuation Analysis: Fair Value Reflects Execution Risks
At the current market price of ₹41.31, Sagility trades at 20.61x trailing twelve-month earnings, representing a 35% discount to the software and consulting sector average P/E of approximately 33x. The company's EV/EBITDA multiple of 11.27x appears reasonable for a BPM player but reflects concerns about margin sustainability and growth momentum. The price-to-book ratio of 2.03x values the company at approximately 2.5 times its ROE-justified multiple (ROE of 8.16% would theoretically support a P/B of around 0.8x for a 10% cost of equity), suggesting the market is pricing in expectations of meaningful ROE improvement.
The stock's PEG ratio of 0.27x appears attractive on the surface, indicating the stock trades at less than one-third of its earnings growth rate. However, this metric should be viewed with caution given the recent sequential decline in profitability and margin compression. The company's EV/Sales ratio of 2.75x is reasonable for a services business but requires margin expansion to justify sustained valuation support.
The valuation appears fair to slightly expensive given current execution challenges. Whilst the company trades at a discount to peers, this discount reflects genuine quality and profitability gaps rather than representing a bargain opportunity. For value to unlock, Sagility must demonstrate: (1) sustained revenue growth resumption, (2) margin stabilisation and expansion back towards 24-25% operating margins, (3) ROE improvement towards 12-15% levels, and (4) consistent execution without quarterly volatility.
Shareholding Pattern: Institutional Confidence Tested
| Category | Jun'26 | Mar'26 | Dec'25 | QoQ Change |
|---|---|---|---|---|
| Promoter | 50.95% | 50.95% | 50.95% | 0.00% |
| FII | 9.99% | 10.02% | 10.25% | -0.03% |
| Mutual Funds | 13.45% | 14.54% | 13.36% | -1.09% |
| Insurance | 4.09% | 3.60% | 3.79% | +0.49% |
| Other DII | 3.88% | 4.14% | 4.21% | -0.26% |
| Non-Institutional | 17.64% | 16.74% | 17.44% | +0.90% |
The shareholding pattern for Q1 FY27 reveals cautious institutional sentiment. Mutual fund holdings declined 109 basis points sequentially to 13.45%, representing the most significant institutional movement during the quarter. This reduction suggests domestic institutional investors are taking profits or reallocating capital following the stock's underperformance. Foreign institutional investors also marginally reduced holdings by 3 basis points to 9.99%, continuing a gradual decline from 10.25% in December 2025.
Promoter holding remains stable at 50.95%, though notably lower than the 67.38% stake held in September 2025, reflecting a significant stake sale that occurred in December 2025. Insurance companies increased exposure by 49 basis points to 4.09%, providing a modest positive signal. The combined institutional holding of 31.41% indicates reasonable but not overwhelming institutional confidence. The increase in non-institutional holdings to 17.64% suggests retail participation has grown, potentially absorbing shares sold by institutions.
Stock Performance: Significant Underperformance Persists
| Period | Stock Return | Sensex Return | Alpha |
|---|---|---|---|
| 1 Week | -1.88% | -0.43% | -1.45% |
| 1 Month | +3.15% | -0.31% | +3.46% |
| 3 Months | -0.72% | -2.12% | +1.40% |
| 6 Months | -21.25% | -6.63% | -14.62% |
| YTD | -20.59% | -9.82% | -10.77% |
| 1 Year | -5.49% | -6.49% | +1.00% |
Sagility's stock performance has been disappointing across most timeframes, with particularly severe underperformance over the past six months. The stock has declined 21.25% over six months compared to the Sensex's 6.63% fall, generating negative alpha of 14.62 percentage points. Year-to-date returns of -20.59% significantly lag the broader market's -9.82% decline, reflecting investor concerns about the company's near-term prospects and execution challenges.
The stock trades at ₹41.31, down 28.65% from its 52-week high of ₹57.90 but 15.33% above its 52-week low of ₹35.82. Technical indicators show a "Mildly Bearish" trend, with the stock trading below all major moving averages including the 200-day moving average of ₹45.19. The high beta of 1.35 indicates the stock is significantly more volatile than the broader market, amplifying both gains and losses. With a volatility of 36.34% compared to the Sensex's 13.53%, Sagility falls into the "High Risk Medium Return" category, making it unsuitable for conservative investors.
Investment Thesis: Show Me Story Requires Validation
Sagility's investment thesis centres on its positioning in the growing healthcare BPM market, with the company demonstrating strong year-on-year growth rates of 27.59% in revenue and 45.94% in net profit for Q1 FY27. The company's specialisation in healthcare payer and provider services provides a defensible niche with recurring revenue characteristics. The balance sheet strength, with debt-to-equity of just 0.12x and robust operating cash flow generation of ₹1,214 crores in FY25, provides financial flexibility for growth investments.
However, significant concerns temper this positive narrative. The sequential revenue decline of 3.00% and profit decline of 15.88% in Q1 FY27 raise questions about business momentum and demand visibility. The sustained margin compression, with operating margins declining from 26.99% in December 2024 to 22.32% currently, indicates either pricing pressures or operational inefficiencies requiring management attention. The company's ROE of 8.16% and ROCE of 12.87% remain substantially below peer averages, suggesting capital is not being deployed efficiently.
Key Strengths & Risk Factors
✅ KEY STRENGTHS
- Strong YoY Growth: Revenue up 27.59% and net profit up 45.94% year-on-year demonstrates underlying business momentum
- Healthcare BPM Specialisation: Focused positioning in healthcare payer/provider services provides defensible niche with recurring revenues
- Conservative Balance Sheet: Debt-to-equity of 0.12x and declining debt levels indicate strong financial health and flexibility
- Robust Cash Generation: Operating cash flow of ₹1,214 crores in FY25 (up from ₹973 crores in FY24) demonstrates healthy underlying cash conversion
- Attractive Valuation: P/E of 20.61x represents 35% discount to sector average, PEG ratio of 0.27x suggests value opportunity if execution improves
- Institutional Participation: Combined institutional holdings of 31.41% indicates credible investor base despite recent reductions
- Improving Quality Grade: Upgraded from "Average" to "Good" quality status reflects long-term financial performance improvements
⚠️ KEY CONCERNS
- Sequential Revenue Decline: 3.00% QoQ revenue contraction in Q1 FY27 breaks growth momentum and raises demand visibility concerns
- Margin Compression: Operating margins declined from 26.99% (Dec'24) to 22.32% (Jun'26), a 467 bps erosion indicating pricing or efficiency issues
- Weak Return Ratios: ROE of 8.16% and ROCE of 12.87% significantly lag peer averages of ~23%, indicating suboptimal capital efficiency
- Profit Decline: Net profit down 15.88% QoQ to ₹216.81 crores despite stable costs suggests operational leverage working in reverse
- Institutional Selling: Mutual fund holdings declined 109 bps QoQ, FII holdings down marginally, indicating cautious institutional sentiment
- Stock Underperformance: 21.25% decline over six months with negative alpha of 14.62% reflects market concerns about execution
- High Volatility: Beta of 1.35 and volatility of 36.34% makes stock unsuitable for risk-averse investors seeking stable returns
Outlook: What to Watch
🟢 POSITIVE CATALYSTS
- Margin Recovery: Management actions to restore operating margins towards 24-25% levels would significantly improve profitability and investor sentiment
- Revenue Growth Resumption: Return to sequential revenue growth in Q2 FY27 would validate demand strength and alleviate momentum concerns
- ROE Improvement: Sustained improvement in return ratios towards 12-15% would narrow quality gap with peers and support valuation re-rating
- New Client Wins: Announcement of significant new client acquisitions or contract expansions would demonstrate competitive positioning strength
- Institutional Buying: Reversal of mutual fund selling trend and increased FII participation would provide technical support and confidence signal
🔴 RED FLAGS
- Continued Revenue Decline: Further sequential revenue contraction in Q2 FY27 would indicate structural demand issues rather than temporary headwinds
- Further Margin Erosion: Operating margins falling below 22% would raise serious questions about business model sustainability and pricing power
- Elevated Attrition: Increasing employee turnover (monitor employee cost trends) could indicate retention challenges and service delivery risks
- Client Concentration: Loss of major clients or reduced spending by key accounts would materially impact revenue and profitability outlook
- Continued Institutional Exodus: Accelerated selling by mutual funds or FIIs would create technical pressure and signal deteriorating confidence
The Verdict: Execution Concerns Warrant Caution
Score: 48/100
For Fresh Investors: Avoid initiating positions at current levels. Whilst the valuation appears reasonable at 20.61x P/E and the company demonstrates strong year-on-year growth, the sequential revenue decline, sustained margin compression, and weak return ratios indicate execution challenges that require resolution. The stock's high volatility (36.34%) and bearish technical trend add to near-term risks. Wait for evidence of margin stabilisation and revenue growth resumption before considering entry.
For Existing Holders: Consider reducing exposure or exiting positions, particularly for those sitting on losses from higher entry points. The 21.25% decline over six months reflects legitimate concerns about profitability sustainability and business momentum. Whilst the long-term growth opportunity in healthcare BPM remains intact, near-term execution risks and margin pressures justify a cautious stance. Those with higher risk tolerance may hold with strict monitoring of Q2 FY27 results for signs of improvement.
Fair Value Estimate: ₹38-40 (8-11% downside from current ₹41.31), based on 18-19x forward P/E applied to normalised earnings assuming 22-23% operating margins and modest revenue growth resumption. Upside scenario of ₹48-50 possible if margins recover to 24-25% and sequential growth resumes strongly.
Note- ROCE= (EBIT - Other income)/(Capital Employed - Cash - Current Investments)
⚠️ Investment Disclaimer
This article is for educational and informational purposes only and should not be construed as financial advice. Investors should conduct their own due diligence, consider their risk tolerance and investment objectives, and consult with a qualified financial advisor before making any investment decisions. Past performance is not indicative of future results. The stock market involves risks, and investors may lose part or all of their invested capital.
